By all measures, the addition of nab-paclitaxel for the treatment of patients with advanced pancreatic cancer was superior to the survival for patients who received only gemcitabine, according to the results of a study led by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, published today by The New England Journal of Medicine.
The study of 861 patients, conducted at 151 community and academic centers in 11 nations, found that the 431 patients assigned nab-paclitaxel—in addition to the standard-of-care gemcitabine—had significantly improved overall survival, progression-free survival, and drug response rates than for the 430 assigned to gemcitabine alone.
"This large, randomized, international, phase 3 study showed that the nab-paclitaxel plus gemcitabine led to a significant improvement in survival at all time points," said Dr. Daniel D. Von Hoff, TGen Distinguished Professor and Physician-In-Chief, and Chief Scientific Officer for the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with TGen.
"The rate of survival was significantly higher in the nab-paclitaxel-gemcitabine group than in the gemcitabine group," said Dr. Von Hoff, lead author among the study's 23 co-authors and more than 130 researchers. He served as Principal Investigator of MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial), which included sites in North America, Europe and Australia.
Dr. Von Hoff, considered among the nation's leading authorities on pancreatic cancer, also was the principal investigator for the first clinical trial of gemcitabine, the first therapy to show improvement in survival for patients with pancreatic cancer. The FDA approved gemcitabine in 1996.
On Sept. 6, the U.S. Food and Drug Administration (FDA) approved nab-paclitaxel (produced by Celgene Corporation under the brand name Abraxane) for use in advanced pancreatic cancer patients. Abraxane previously was approved by the FDA for use in the treatment of metastatic breast cancer (2005) and advanced lung cancer (2012).
While it is still uncertain exactly how Abraxane works, Abraxane wraps traditional chemotherapy, paclitaxel, in near-nano sized shells of albumin, a protein that the tumor could recognize as food. Once inside the tumor, the Abraxane may act like a "Trojan Horse" to release chemotherapy and kill the cancer cells.
Participants treated with Abraxane plus gemcitabine lived, on average, 1.8 months longer than those treated with gemcitabine alone, and they experienced a delay in tumor growth (progression-free survival) that was, on average, 1.8 months later than the participants who only received gemcitabine.
Of note, 35 percent of patients who also received Abraxane survived more than 1 year, a 59 percent increase over the 22 percent of those receiving only gemcitabine who survived more than 1 year. Also, more than twice as many patients (9 percent) who also received Abraxane survived more than 2 years, compared to those (4 percent) who only received gemcitabine.
"This a major breakthrough, but there is more work to be done. Building on these results, we are evaluating new targeted agents in combination with the Abraxane/gemcitabine regimen," said Dr. Ramesh Ramanathan, Medical Director of the Virginia G. Cancer Center Clinical Trials at Scottsdale Healthcare, and MPACT principal investigator for the United States.
The most significant side effect from the addition of nab-paclitaxel was peripheral neuropathy, such as numbness in the hands and feet, although this occurred in only a small proportion of patients and was "rapidly reversible in most patients" by temporarily halting the drug and subsequently reducing its dosage. None of the patients experienced severe (grade 4) neuropathy.
The pancreas is a glandular organ behind the stomach that secretes enzymes to help digestion, and produces hormones, including insulin, which helps regulate blood-sugar metabolism.
"We are very grateful to the Seena Magowitz Foundation and to the Bedding Industry, which supported the research, leading to this important new survival-improving combination therapy," said Dr. Von Hoff. "We also appreciate the support of Stand Up To Cancer."
Explore further: Phase III worldwide study of new drug for patients with pancreatic cancer
Medical Xpress on facebook
Related Stories
Phase III worldwide study of new drug for patients with pancreatic cancer
Nov 19, 2012
A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment, according to results of a Phase III clinical ...
Study shows drug combination extends pancreatic cancer patient survival
Jan 22, 2013
A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard ...
Results of new drug for pancreatic cancer patients published
Oct 04, 2011
Patients at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare were the first in the nation to participate in a clinical trial to determine the safety, tolerability and effectiveness for usage of a new ...
Chemotherapy drug improves survival following surgery for pancreatic cancer
Oct 08, 2013
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation ...
Combination therapy may enhance gemcitabine activity
Feb 28, 2012
Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer Di ...
Recommended for you
Blood test can differentiate between benign lung nodules and early stage lung cancer, study suggest
3 hours ago
Indi (Integrated Diagnostics), an emerging leader in molecular diagnostics, today announced the results of a major study which suggests that quantifying a combination of blood proteins can distinguish between benign lung ...
Genetic errors identified in 12 major cancer types
4 hours ago
Examining 12 major types of cancer, scientists at Washington University School of Medicine in St. Louis have identified 127 repeatedly mutated genes that appear to drive the development and progression of ...
Patients with poor nutrition before bladder cancer operation have higher risk of complications
5 hours ago
Patients with bladder cancer are two times more likely to have complications after a radical cystectomy procedure if they have a biomarker for poor nutritional status before the operation, according to study findings presented ...
Light triggers death switch in cancer cells
5 hours ago
Researchers at Cardiff University have created a peptide (a small piece of protein), linked to a light-responsive dye, capable of switching 'on' death pathways in cancer cells. The peptide remains inactive until exposed to ...
ACG: Physical activity linked to lower risk of esophageal cancer
7 hours ago
(HealthDay)—Physical activity is associated with a reduced risk of esophageal cancer (EC), according to a review and meta-analysis presented at the annual meeting of the American College of Gastroenterology, ...
Blood test shows promise for cancer detection, study finds
7 hours ago
(HealthDay)—Researchers say they've developed a blood test that can detect some cases of early stage lung and prostate cancer.
User comments
© Medical Xpress 2011-2013, Phys.org network
By all measures, the addition of nab-paclitaxel for the treatment of patients with advanced pancreatic cancer was superior to the survival for patients who received only gemcitabine, according to the results of a study led by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, published today by The New England Journal of Medicine.
The study of 861 patients, conducted at 151 community and academic centers in 11 nations, found that the 431 patients assigned nab-paclitaxel—in addition to the standard-of-care gemcitabine—had significantly improved overall survival, progression-free survival, and drug response rates than for the 430 assigned to gemcitabine alone.
"This large, randomized, international, phase 3 study showed that the nab-paclitaxel plus gemcitabine led to a significant improvement in survival at all time points," said Dr. Daniel D. Von Hoff, TGen Distinguished Professor and Physician-In-Chief, and Chief Scientific Officer for the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with TGen.
"The rate of survival was significantly higher in the nab-paclitaxel-gemcitabine group than in the gemcitabine group," said Dr. Von Hoff, lead author among the study's 23 co-authors and more than 130 researchers. He served as Principal Investigator of MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial), which included sites in North America, Europe and Australia.
Dr. Von Hoff, considered among the nation's leading authorities on pancreatic cancer, also was the principal investigator for the first clinical trial of gemcitabine, the first therapy to show improvement in survival for patients with pancreatic cancer. The FDA approved gemcitabine in 1996.
On Sept. 6, the U.S. Food and Drug Administration (FDA) approved nab-paclitaxel (produced by Celgene Corporation under the brand name Abraxane) for use in advanced pancreatic cancer patients. Abraxane previously was approved by the FDA for use in the treatment of metastatic breast cancer (2005) and advanced lung cancer (2012).
While it is still uncertain exactly how Abraxane works, Abraxane wraps traditional chemotherapy, paclitaxel, in near-nano sized shells of albumin, a protein that the tumor could recognize as food. Once inside the tumor, the Abraxane may act like a "Trojan Horse" to release chemotherapy and kill the cancer cells.
Participants treated with Abraxane plus gemcitabine lived, on average, 1.8 months longer than those treated with gemcitabine alone, and they experienced a delay in tumor growth (progression-free survival) that was, on average, 1.8 months later than the participants who only received gemcitabine.
Of note, 35 percent of patients who also received Abraxane survived more than 1 year, a 59 percent increase over the 22 percent of those receiving only gemcitabine who survived more than 1 year. Also, more than twice as many patients (9 percent) who also received Abraxane survived more than 2 years, compared to those (4 percent) who only received gemcitabine.
"This a major breakthrough, but there is more work to be done. Building on these results, we are evaluating new targeted agents in combination with the Abraxane/gemcitabine regimen," said Dr. Ramesh Ramanathan, Medical Director of the Virginia G. Cancer Center Clinical Trials at Scottsdale Healthcare, and MPACT principal investigator for the United States.
The most significant side effect from the addition of nab-paclitaxel was peripheral neuropathy, such as numbness in the hands and feet, although this occurred in only a small proportion of patients and was "rapidly reversible in most patients" by temporarily halting the drug and subsequently reducing its dosage. None of the patients experienced severe (grade 4) neuropathy.
The pancreas is a glandular organ behind the stomach that secretes enzymes to help digestion, and produces hormones, including insulin, which helps regulate blood-sugar metabolism.
"We are very grateful to the Seena Magowitz Foundation and to the Bedding Industry, which supported the research, leading to this important new survival-improving combination therapy," said Dr. Von Hoff. "We also appreciate the support of Stand Up To Cancer."
Explore further: Phase III worldwide study of new drug for patients with pancreatic cancer
Medical Xpress on facebook
Related Stories
Phase III worldwide study of new drug for patients with pancreatic cancer
Nov 19, 2012
A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment, according to results of a Phase III clinical ...
Study shows drug combination extends pancreatic cancer patient survival
Jan 22, 2013
A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard ...
Results of new drug for pancreatic cancer patients published
Oct 04, 2011
Patients at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare were the first in the nation to participate in a clinical trial to determine the safety, tolerability and effectiveness for usage of a new ...
Chemotherapy drug improves survival following surgery for pancreatic cancer
Oct 08, 2013
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation ...
Combination therapy may enhance gemcitabine activity
Feb 28, 2012
Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer Di ...
Recommended for you
Blood test can differentiate between benign lung nodules and early stage lung cancer, study suggest
3 hours ago
Indi (Integrated Diagnostics), an emerging leader in molecular diagnostics, today announced the results of a major study which suggests that quantifying a combination of blood proteins can distinguish between benign lung ...
Genetic errors identified in 12 major cancer types
4 hours ago
Examining 12 major types of cancer, scientists at Washington University School of Medicine in St. Louis have identified 127 repeatedly mutated genes that appear to drive the development and progression of ...
Patients with poor nutrition before bladder cancer operation have higher risk of complications
5 hours ago
Patients with bladder cancer are two times more likely to have complications after a radical cystectomy procedure if they have a biomarker for poor nutritional status before the operation, according to study findings presented ...
Light triggers death switch in cancer cells
5 hours ago
Researchers at Cardiff University have created a peptide (a small piece of protein), linked to a light-responsive dye, capable of switching 'on' death pathways in cancer cells. The peptide remains inactive until exposed to ...
ACG: Physical activity linked to lower risk of esophageal cancer
7 hours ago
(HealthDay)—Physical activity is associated with a reduced risk of esophageal cancer (EC), according to a review and meta-analysis presented at the annual meeting of the American College of Gastroenterology, ...
Blood test shows promise for cancer detection, study finds
7 hours ago
(HealthDay)—Researchers say they've developed a blood test that can detect some cases of early stage lung and prostate cancer.
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment